
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3020138/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An organoid model of colorectal circulating tumor cells with stem cell features, hybrid EMT state and distinctive therapy response profile. Journal of Experimental and Clinical Cancer Research, 2022, 41, 86.	8.6	31
2	Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial Journal of Clinical Oncology, 2022, 40, 3087-3087.	1.6	2
3	Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51. Cell Death and Differentiation, 2021, 28, 2060-2082.	11.2	19
4	Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry. European Journal of Haematology, 2021, 107, 408-415.	2.2	0
5	Elesclomol-induced increase of mitochondrial reactive oxygen species impairs glioblastoma stem-like cell survival and tumor growth. Journal of Experimental and Clinical Cancer Research, 2021, 40, 228.	8.6	45
6	Theratyping cystic fibrosis <i>in vitro</i> in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells. European Respiratory Journal, 2021, 58, 2100908.	6.7	39
7	qSNE: quadratic rate t-SNE optimizer with automatic parameter tuning for large datasets. Bioinformatics, 2020, 36, 5086-5092.	4.1	3
8	Different Mechanisms Underlie the Metabolic Response of GBM Stem-Like Cells to Ionizing Radiation: Biological and MRS Studies on Effects of Photons and Carbon Ions. International Journal of Molecular Sciences, 2020, 21, 5167.	4.1	8
9	COVID-19–Induced Modifications in the Tumor Microenvironment: Do They Affect Cancer Reawakening and Metastatic Relapse?. Frontiers in Oncology, 2020, 10, 592891.	2.8	22
10	Mir-370-3p Impairs Glioblastoma Stem-Like Cell Malignancy Regulating a Complex Interplay between HMGA2/HIF1A and the Oncogenic Long Non-Coding RNA (IncRNA) NEAT1. International Journal of Molecular Sciences, 2020, 21, 3610.	4.1	25
11	Deregulated expression of the imprinted <i>DLK1-DIO3</i> region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3. Neuro-Oncology, 2020, 22, 1771-1784.	1.2	44
12	Multicentre Harmonisation of a Six-Colour Flow Cytometry Panel for NaÃ⁻ve/Memory T Cell Immunomonitoring. Journal of Immunology Research, 2020, 2020, 1-15.	2.2	8
13	Joint action of miRâ€126 and MAPK/PI3K inhibitors against metastatic melanoma. Molecular Oncology, 2019, 13, 1836-1854.	4.6	15
14	Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells. Cancer Immunology Research, 2018, 6, 658-670.	3.4	34
15	Two-Step Coimmunoprecipitation (TIP) Enables Efficient and Highly Selective Isolation of Native Protein Complexes. Molecular and Cellular Proteomics, 2018, 17, 993-1009.	3.8	8
16	Metabolic Heterogeneity Evidenced by MRS among Patient-Derived Glioblastoma Multiforme Stem-Like Cells Accounts for Cell Clustering and Different Responses to Drugs. Stem Cells International, 2018, 2018, 1-16.	2.5	29
17	A threeâ€microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes. Molecular Oncology, 2017, 11, 1115-1129.	4.6	32
18	The clinical value of patient-derived glioblastoma tumorspheres in predicting treatment response. Neuro-Oncology, 2017, 19, 1097-1108.	1.2	56

#	Article	IF	CITATIONS
19	Integrin α7 Is a Functional Marker and Potential Therapeutic Target in Glioblastoma. Cell Stem Cell, 2017, 21, 35-50.e9.	11.1	101
20	Cripto is essential to capture mouse epiblast stem cell and human embryonic stem cell pluripotency. Nature Communications, 2016, 7, 12589.	12.8	56
21	Metabolic/Proteomic Signature Defines Two Glioblastoma Subtypes With Different Clinical Outcome. Scientific Reports, 2016, 6, 21557.	3.3	75
22	Generation, Quantification, and Tracing of Metabolically Labeled Fluorescent Exosomes. Methods in Molecular Biology, 2016, 1448, 217-235.	0.9	17
23	Lamina Propria CD4+LAP+ Regulatory T Cells Are Increased in Active Ulcerative Colitis but Show Increased IL-17 Expression and Reduced Suppressor Activity. Journal of Crohn's and Colitis, 2016, 10, 346-353.	1.3	19
24	Molecular profiles of cancer stem-like cell populations in aggressive thyroid cancers. Endocrine, 2016, 53, 145-156.	2.3	16
25	IFN-α potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer. Oncotarget, 2016, 7, 26361-26373.	1.8	25
26	UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response. Oncotarget, 2016, 7, 44113-44128.	1.8	17
27	miR-21 is overexpressed in NPM1-mutant acute myeloid leukemias. Leukemia Research, 2015, 39, 221-228.	0.8	27
28	¹ H NMR spectroscopy of glioblastoma stemâ€like cells identifies alphaâ€aminoadipate as a marker of tumor aggressiveness. NMR in Biomedicine, 2015, 28, 317-326.	2.8	27
29	Glioblastoma stem cells: radiobiological response to ionising radiations of different qualities. Radiation Protection Dosimetry, 2015, 166, 374-378.	0.8	11
30	Two-Year Follow-Up of Macaques Developing Intermittent Control of the Human Immunodeficiency Virus Homolog Simian Immunodeficiency Virus SIVmac251 in the Chronic Phase of Infection. Journal of Virology, 2015, 89, 7521-7535.	3.4	20
31	TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells. Oncogene, 2015, 34, 681-690.	5.9	287
32	The MUTYH base excision repair gene protects against inflammation-associated colorectal carcinogenesis. Oncotarget, 2015, 6, 19671-19684.	1.8	11
33	miR-135b suppresses tumorigenesis in glioblastoma stem-like cells impairing proliferation, migration and self-renewal. Oncotarget, 2015, 6, 37241-37256.	1.8	42
34	Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo. Cell Death and Disease, 2014, 5, e1223-e1223.	6.3	57
35	CD44v6 Is a Marker of Constitutive and Reprogrammed Cancer Stem Cells Driving Colon Cancer Metastasis. Cell Stem Cell, 2014, 14, 342-356.	11.1	617
36	¹ H NMR detects different metabolic profiles in glioblastoma stemâ€like cells. NMR in Biomedicine, 2014, 27, 129-145.	2.8	24

#	Article	IF	CITATIONS
37	Antitumor effect of miR-197 targeting in p53 wild-type lung cancer. Cell Death and Differentiation, 2014, 21, 774-782.	11.2	86
38	Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer. Cell Death and Differentiation, 2014, 21, 1877-1888.	11.2	90
39	Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics. Journal of Molecular Endocrinology, 2014, 52, 121-131.	2.5	41
40	Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression. Oncogene, 2013, 32, 4806-4813.	5.9	159
41	BTG2 loss and miR-21 upregulation contribute to prostate cell transformation by inducing luminal markers expression and epithelial–mesenchymal transition. Oncogene, 2013, 32, 1843-1853.	5.9	94
42	Mek inhibition results in marked antitumor activity against metastatic melanoma patient-derived melanospheres and in melanosphere-generated xenografts. Journal of Experimental and Clinical Cancer Research, 2013, 32, 91.	8.6	18
43	Erythropoietin Activates Cell Survival Pathways in Breast Cancer Stem–like Cells to Protect Them from Chemotherapy. Cancer Research, 2013, 73, 6393-6400.	0.9	37
44	DNA damage response in monozygotic twins discordant for smoking habits. Mutagenesis, 2013, 28, 135-144.	2.6	7
45	BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition. Carcinogenesis, 2013, 34, 2558-2567.	2.8	23
46	miR-126&126* Restored Expressions Play a Tumor Suppressor Role by Directly Regulating ADAM9 and MMP7 in Melanoma. PLoS ONE, 2013, 8, e56824.	2.5	80
47	Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy. Cell Death and Differentiation, 2012, 19, 768-778.	11.2	157
48	Proliferation State and Polo-Like Kinase1 Dependence of Tumorigenic Colon Cancer Cells. Stem Cells, 2012, 30, 1819-1830.	3.2	53
49	A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells. PLoS ONE, 2012, 7, e35073.	2.5	41
50	EGFR Inhibition Abrogates Leiomyosarcoma Cell Chemoresistance through Inactivation of Survival Pathways and Impairment of CSC Potential. PLoS ONE, 2012, 7, e46891.	2.5	36
51	Human Haemato-Endothelial Precursors: Cord Blood CD34+ Cells Produce Haemogenic Endothelium. PLoS ONE, 2012, 7, e51109.	2.5	23
52	Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene, 2011, 30, 4231-4242.	5.9	221
53	Expression of the stem cell marker CD133 in recurrent glioblastoma and its value for prognosis. Cancer, 2011, 117, 162-174.	4.1	80
54	Prevention of Chemotherapy-Induced Anemia and Thrombocytopenia by Constant Administration of Stem Cell Factor. Clinical Cancer Research, 2011, 17, 6185-6191.	7.0	24

#	Article	IF	CITATIONS
55	Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO Journal, 2010, 29, 2646-2658.	7.8	208
56	Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature, 2010, 468, 824-828.	27.8	1,235
57	Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. Endocrine-Related Cancer, 2010, 17, 823-833.	3.1	58
58	Thymosin β4 targeting impairs tumorigenic activity of colon cancer stem cells. FASEB Journal, 2010, 24, 4291-4301.	0.5	33
59	New models for cancer research: human cancer stem cell xenografts. Current Opinion in Pharmacology, 2010, 10, 380-384.	3.5	47
60	MicroRNA 223-dependent expression of LMO2 regulates normal erythropoiesis. Haematologica, 2009, 94, 479-486.	3.5	143
61	Caveolinâ€1 tumorâ€promoting role in human melanoma. International Journal of Cancer, 2009, 125, 1514-1522.	5.1	96
62	High sensitivity of ovarian cancer cells to the synthetic triterpenoid CDDO-Imidazolide. Cancer Letters, 2009, 282, 214-228.	7.2	24
63	NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls Î ² -globin and G-CSF receptor expression. Blood, 2009, 114, 1753-1763.	1.4	57
64	A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nature Cell Biology, 2008, 10, 788-801.	10.3	214
65	The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nature Medicine, 2008, 14, 1271-1277.	30.7	919
66	Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death and Differentiation, 2008, 15, 504-514.	11.2	1,511
67	MicroRNA 155 modulates megakaryopoiesis at progenitor and precursor level by targeting Etsâ€1 and Meis1 transcription factors. British Journal of Haematology, 2008, 143, 570-580.	2.5	87
68	Isolation and characterization of CD146+ multipotent mesenchymal stromal cells. Experimental Hematology, 2008, 36, 1035-1046.	0.4	240
69	MicroRNA-221/-222 pathway controls melanoma progression. European Journal of Cancer, Supplement, 2008, 6, 122.	2.2	1
70	The Promyelocytic Leukemia Zinc Finger–MicroRNA-221/-222 Pathway Controls Melanoma Progression through Multiple Oncogenic Mechanisms. Cancer Research, 2008, 68, 2745-2754.	0.9	357
71	Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells, Molecules, and Diseases, 2007, 39, 82-91.	1.4	145
72	Human neural progenitor cells display limited cytotoxicity and increased oligodendrogenesis during inflammation. Cell Death and Differentiation, 2007, 14, 876-878.	11.2	16

#	Article	IF	CITATIONS
73	Identification and expansion of human colon-cancer-initiating cells. Nature, 2007, 445, 111-115.	27.8	3,690
74	Methylation damage response in hematopoietic progenitor cells. DNA Repair, 2007, 6, 1170-1178.	2.8	13
75	A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecologic Oncology, 2007, 105, 481-492.	1.4	35
76	Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis: an International Journal on Programmed Cell Death, 2007, 12, 635-655.	4.9	47
77	Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells, Molecules, and Diseases, 2006, 37, 218-225.	1.4	22
78	Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood, 2005, 106, 2527-2529.	1.4	41
79	Recombinant Tumor-Associated MUC1 Glycoprotein Impairs the Differentiation and Function of Dendritic Cells. Journal of Immunology, 2005, 174, 7764-7772.	0.8	82
80	Multiple Members of the TNF Superfamily Contribute to IFN-γ-Mediated Inhibition of Erythropoiesis. Journal of Immunology, 2005, 175, 1464-1472.	0.8	81
81	False-positive Finding on 18F-FDG PET after Chemotherapy for Primary Diffuse Large B-cell Lymphoma of the Thyroid: a Case Report. Japanese Journal of Clinical Oncology, 2004, 34, 280-281.	1.3	11
82	Production of interferon-Î ³ by lymphocytes from paroxysmal nocturnal haemoglobinuria patients: relationship with clinical status. British Journal of Haematology, 2004, 124, 685-690.	2.5	8
83	Monoclonal antibodies against Candida rugosa lipase. Journal of Molecular Catalysis B: Enzymatic, 2004, 28, 71-74.	1.8	14
84	Lymphocyte T subsets and natural killer cells in Italian and Philippino blood donors. Vox Sanguinis, 2003, 84, 68-72.	1.5	5
85	Regulated expression of MUC1 epithelial antigen in erythropoiesis. British Journal of Haematology, 2003, 120, 344-352.	2.5	19
86	Transfected human dendritic cells to induce antitumor immunity. Gene Therapy, 2000, 7, 1458-1466.	4.5	41
87	AN IL-6/IL-6 SOLUBLE RECEPTOR (IL-6R) HYBRID PROTEIN (H-IL-6) INDUCES EPO-INDEPENDENT ERYTHROID DIFFERENTIATION IN HUMAN CD34+CELLS. Cytokine, 2000, 12, 1395-1399.	3.2	4
88	Effects of urinary gonadotrophin preparations on human in-vitro immune function. Human Reproduction, 1998, 13, 2430-2434.	0.9	18
89	Effects of β-casomorphins and Met-enkephalin on human natural killer activity. Pharmacological Research, 1992, 26, 164-165.	7.1	4
90	RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. International Journal of Oncology, 0, , .	3.3	28

#	Article	IF	CITATIONS
91	MiR-378a-3p Acts as a Tumor Suppressor in Colorectal Cancer Stem-Like Cells and Affects the Expression of MALAT1 and NEAT1 IncRNAs. Frontiers in Oncology, 0, 12, .	2.8	5